Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Qiagen is a Netherlands-based provider of sample and assay technologies for molecular diagnostics, applied testing, pharmaceutical research, and academic life sciences. The company operates across 35+ locations globally with a portfolio of over 500 consumable product groups and automated workflow solutions, serving clinical laboratories, pharma/biotech companies, and academic institutions. Competitive positioning centers on proprietary sample preparation technologies and an installed base of automated instruments that drive recurring consumable revenues.
Qiagen employs a razor-razorblade model where automated instruments (QIAsymphony, QIAcube platforms) are placed at customer sites, generating recurring high-margin consumable revenues from proprietary reagent kits and sample prep cartridges. Pricing power derives from workflow integration, regulatory clearances (FDA/CE-IVD), and switching costs once laboratories validate protocols. The company benefits from multi-year pharma partnerships for companion diagnostics development and royalty streams from licensed technologies. Gross margins of 62% reflect consumable mix and manufacturing scale in Germany and China facilities.
Molecular diagnostics consumable growth rates, particularly oncology and infectious disease testing volumes in clinical labs
Pharma/biotech R&D spending trends affecting Life Sciences segment demand for sample prep kits and NGS workflow products
New product launch momentum for QuantiFERON-TB, QIAstat-Dx syndromic testing, and liquid biopsy assays with associated reimbursement approvals
Instrument placements (QIAsymphony, QIAcube Connect) driving future consumable pull-through at 3-5x instrument revenue over lifecycle
Currency headwinds given ~40% USD revenue exposure and euro-based cost structure
Technology disruption from next-generation sequencing cost declines potentially commoditizing sample preparation workflows, with Illumina vertical integration and Oxford Nanopore direct-from-sample sequencing bypassing traditional extraction steps
Reimbursement pressure in molecular diagnostics as payers scrutinize high-cost genetic testing, particularly in oncology panels where $3,000-5,000 test prices face coverage restrictions
Regulatory pathway complexity for companion diagnostics requiring parallel FDA/EMA approvals with pharma partners, creating 3-5 year development timelines and approval risk
Thermo Fisher and Roche Diagnostics compete across sample prep and molecular diagnostics with broader portfolios and larger commercial scale, leveraging integrated instrument-consumable ecosystems
Chinese local competitors (BGI, Daan Gene) gaining share in Asia-Pacific with 30-40% lower pricing on PCR reagents and extraction kits, particularly in cost-sensitive research markets
Vertical integration by large diagnostic labs (Quest, LabCorp) developing in-house assays to reduce per-test costs, disintermediating third-party reagent suppliers
Moderate leverage at 0.44x debt/equity is manageable but limits M&A capacity for transformative acquisitions in competitive consolidating market where peers execute $500M+ deals
Euro functional currency creates translation risk with ~40% USD revenues; 10% dollar strengthening reduces reported revenues by $80-90M annually absent hedging
Pension obligations and restructuring charges periodically impact reported earnings, though $700M operating cash flow provides cushion
moderate - Clinical diagnostics revenues (~40% of total) exhibit defensive characteristics tied to healthcare utilization rather than GDP, though elective testing volumes can fluctuate. Life Sciences segment shows higher cyclicality linked to pharma/biotech R&D budgets and academic grant funding, which contract during recessions. Applied Testing (forensics/food safety) is relatively stable. Overall, 60% revenue exposure to research markets creates moderate GDP sensitivity.
Rising rates create modest headwinds through two channels: (1) Biotech funding environment tightens, reducing customer R&D budgets and delaying instrument purchases, particularly impacting Life Sciences segment growth. (2) Higher discount rates compress valuation multiples for med-tech growth stocks trading at 15-20x EBITDA. However, minimal direct impact given low debt/equity of 0.44x and limited refinancing risk. Rate increases above 5% historically correlate with 10-15% biotech VC funding declines.
Minimal direct credit exposure given customer base of hospital systems, government labs, and investment-grade pharma companies with low default risk. Indirect exposure exists if credit tightening reduces biotech startup formation or academic research funding, impacting Life Sciences consumable demand. Strong current ratio of 3.9x and operating cash flow generation provide internal funding capacity independent of credit markets.
value - Stock trades at 15x EBITDA versus 20-25x for high-growth diagnostics peers, attracting value investors seeking stable cash flows and modest growth. Defensive healthcare exposure with 4.5% FCF yield appeals to quality-focused funds. Limited dividend (reinvestment in R&D prioritized) reduces income investor appeal. Institutional ownership concentrated among healthcare specialists recognizing consumable recurring revenue model.
moderate - Beta typically 0.8-1.0 reflecting healthcare sector defensiveness offset by growth stock characteristics. Quarterly volatility driven by FX translation impacts (euro reporting), lumpy instrument placements, and biotech funding cycle sentiment. Less volatile than pure-play diagnostics given diversified end-market exposure across clinical, research, and applied testing.
